Protein / target

1,3-beta-glucan synthase

GSC1O13428Candida albicans

UniProt: O13428

Clinical trials

Drugs targeting

Protein at a glance

Biological role

1,3-beta-D-glucan synthase

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Subcellular location

Membrane

Domains and Gene Ontology detail (6)

Domains & features

1,3-beta-glucan synthase component FKS1-like

Gene Ontology

C1,3-beta-D-glucan synthase complex
Cplasma membrane
F1,3-beta-D-glucan synthase activity
P(1->3)-beta-D-glucan biosynthetic process
Pfungal-type cell wall polysaccharide biosynthetic process

1897 aa · 218 kDa

Approved medicines with mapped indications

1 medicine · 2 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Candidemia1 medicine

anidulafungin

Candidiasis1 medicine

anidulafungin

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

anidulafungin

Narrow target profileInhibitor

1,3-beta-glucan synthase inhibitor

Indicated for Candidemia, Candidiasis

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Clinical trials

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in ICU PatientsPHASE4

COMPLETED · via anidulafungin · NCT01734525

Multicenter, Randomized, Open-label Clinical Trial to Compare Anidulafungin Versus Amphotericin B Safety in High Risk Hepatic Transplant RecipientsPHASE4

COMPLETED · via anidulafungin · NCT01303549

Population Pharmacokinetic Analysis of Anidulafungin in Normal, Overweight and Obese VolunteersPHASE4

COMPLETED · via anidulafungin · NCT01307930

Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind TrialPHASE4

COMPLETED · via anidulafungin · NCT00841971

View all trials (17)

Phase IV Open-Label Pilot Study to Evaluate the Combination of Voriconazole and Anidulafungin for the Treatment of Subjects With Proven or Probable Invasive Aspergillosis Who Are Intolerant of Polyene TreatmentPHASE4

TERMINATED · via anidulafungin · NCT00620074

Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole, For Treatment Of Documented Candidemia/Invasive Candidiasis In Hospitalized PatientsPHASE4

COMPLETED · via anidulafungin · NCT00548262

Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive CandidiasisPHASE4

COMPLETED · via anidulafungin · NCT00496197

Azole-echinocandin Combination Therapy for Invasive Aspergillosis A Randomized Pragmatic Superiority TrialPHASE3

TERMINATED · via anidulafungin · NCT04876716

A Prospective, Randomized Trial Comparing The Safety, Tolerability, And Efficacy Of Voriconazole And Anidulafungin In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Invasive Aspergillosis in Pediatric Subjects Aged 2 to 17 YearsPHASE3

WITHDRAWN · via anidulafungin · NCT01188759

A PROSPECTIVE, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY & EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS, INCLUDING CANDIDEMIAPHASE3

COMPLETED · via anidulafungin · NCT00761267

A Prospective, Randomized Trial Comparing The Efficacy Of Anidulafungin And Voriconazole In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Proven Or Probable Invasive AspergillosisPHASE3

COMPLETED · via anidulafungin · NCT00531479

Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient PopulationsPHASE3

COMPLETED · via anidulafungin · NCT00689338

A Phase IIIB Pilot Study Of Efficacy And Safety Of Anidulafungin In The Treatment Of Candidemia In Asian PatientsPHASE3

COMPLETED · via anidulafungin · NCT00537329

A Phase III, Double Blind, Randomized, Multi-Center Study of the Safety and Efficacy of Anidulafungin VS. Fluconazole in the Treatment of Patients With Candidemia and Other Forms of Invasive Candidiasis and Prevention of ComplicationsPHASE3

COMPLETED · via anidulafungin · NCT00058682

A Phase III, Double-Blind, Randomized, Multi-Center, Study of the Safety and Efficacy of Anidulafungin vs. Fluconazole in the Treatment of Patients With Candidemia and Other Forms of Invasive Candidiasis and Prevention of Complications.PHASE3

COMPLETED · via anidulafungin · NCT00056368

Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment (The CANTREAT Study): A Prospective, Randomized, Double Blind, Placebo Controlled Pilot StudyPHASE2

TERMINATED · via anidulafungin · NCT00934934

Anidulafungin in Patients With Hematologic Malignancies - An Open-label, Prospective Study to Evaluate the Safety Profile at Prophylactic and Therapeutic DosagesPHASE2

TERMINATED · via anidulafungin · NCT01053884

The Pharmacokinetics of Anidulafungin During Continuous Venovenous HemofiltrationPHASE2

UNKNOWN · via anidulafungin · NCT00892359

Phase I/II Study of the Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With Fever and NeutropeniaPHASE1/PHASE2

COMPLETED · via anidulafungin · NCT00056381

Phase I-II Study of the Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With NeutropeniaPHASE1/PHASE2

COMPLETED · via anidulafungin · NCT00068471

Anidulafungin PK in Infants and ToddlersPHASE1

COMPLETED · via anidulafungin · NCT00734500

ClinicalTrials.gov via the drug-target graph.

What's happening now

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

Regulatory approval2007-09-20
Approval: Ecalta (EMA)
ema · regulatory · ema · via anidulafungin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.